Tumor News and Research

RSS

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Double-balloon endoscopy reveals intestinal lipomas within jejunal duplication cysts

Lipoma of the small intestine is a benign tumor of mesenchymal origin which is mostly found by chance during gastrointestinal investigation. Invaginations account for 2/3 of small bowel occlusion caused by up to 80% of tumors and the lipoma is the most frequent benign tumor that causes invagination in its submucous polypoid and it is in more or less scissile form.

10 May 2010

Animal study reveals intestinal bacteria can promote tumor growth

A team of University of California, San Diego School of Medicine researchers has discovered that common intestinal bacteria appear to promote tumor growths in genetically susceptible mice, but that tumorigenesis can be suppressed if the mice are exposed to an inhibiting protein enzyme.

10 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Colorectal cancer is one of the major causes of cancer death in the developed countries. Accumulated evidences indicate that lipid metabolism, especially the one in the arachidonic acid -pathway, appears to play a critical role in the development of CRC.

7 May 2010

Chemical changes in genetic material regulate activity of many genes

Chemical changes in the genetic material, known as epigenetic modifications, regulate the activity of many genes. Thus, attachment of methyl groups to DNA often inactivates important cellular growth brakes. Therefore, this process called methylation is believed to be a major cause of uncontrolled division of cancer cells. Specific enzymes, the DNA methyltransferases, are responsible for methylation.

7 May 2010

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Gastric cancer is the most common malignant gastrointestinal cancer and accounts for 25% of cancer deaths. Nuclear matrix, a filamentous protein framework for eukaryotic cellular chromatin, closely relates to DNA duplication and transcription. Research on nuclear matrix proteins will provide insight into how tumors developed.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from the lowest grade 1 to highest grade 4, with glioblastoma multiforme being the highest grade and deadliest type of glioma.

7 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction. Their findings were published in the April 2010 online edition of BJU International.

6 May 2010

Study aims to clarify expression patterns of CD24 in NSCLC

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance.

6 May 2010

Scientists analyze genetic networks of microRNAs in tumors

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships. Researchers are now discovering how biological networks change and are rewired in cancer.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

Tumor News and Research

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Double-balloon endoscopy reveals intestinal lipomas within jejunal duplication cysts

Animal study reveals intestinal bacteria can promote tumor growth

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Chemical changes in genetic material regulate activity of many genes

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Progestins increase chances of cancer metastasizing: Study

Curis reports net income of $4.8M for first-quarter 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

Study aims to clarify expression patterns of CD24 in NSCLC

Scientists analyze genetic networks of microRNAs in tumors

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News